ATE254615T1 - C-21 modifizierte epothilone - Google Patents

C-21 modifizierte epothilone

Info

Publication number
ATE254615T1
ATE254615T1 AT00910219T AT00910219T ATE254615T1 AT E254615 T1 ATE254615 T1 AT E254615T1 AT 00910219 T AT00910219 T AT 00910219T AT 00910219 T AT00910219 T AT 00910219T AT E254615 T1 ATE254615 T1 AT E254615T1
Authority
AT
Austria
Prior art keywords
modified epothilones
epothilones
modified
Prior art date
Application number
AT00910219T
Other languages
English (en)
Inventor
Gerhard Hoefle
Nicole Glaser
Thomas Leibold
Gregory Vite
Soong-Hoon Kim
Original Assignee
Biotechnolog Forschung Gmbh
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de
Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de
Application filed by Biotechnolog Forschung Gmbh, Bristol Myers Squibb Co filed Critical Biotechnolog Forschung Gmbh
Application granted granted Critical
Publication of ATE254615T1 publication Critical patent/ATE254615T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT00910219T 1999-02-22 2000-02-17 C-21 modifizierte epothilone ATE254615T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999107588 DE19907588A1 (de) 1999-02-22 1999-02-22 C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de) 1999-07-01 1999-07-01 C-21 Modifizierte Epothilone
PCT/US2000/004068 WO2000050423A1 (en) 1999-02-22 2000-02-17 C-21 modified epothilones

Publications (1)

Publication Number Publication Date
ATE254615T1 true ATE254615T1 (de) 2003-12-15

Family

ID=26051995

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910219T ATE254615T1 (de) 1999-02-22 2000-02-17 C-21 modifizierte epothilone

Country Status (37)

Country Link
US (1) US6262094B1 (de)
EP (1) EP1157023B1 (de)
JP (1) JP4598957B2 (de)
KR (1) KR100685336B1 (de)
CN (1) CN1205208C (de)
AR (1) AR028815A1 (de)
AT (1) ATE254615T1 (de)
AU (1) AU771089B2 (de)
BG (1) BG64987B1 (de)
BR (1) BR0008379A (de)
CA (1) CA2360452C (de)
CO (1) CO5140093A1 (de)
CZ (1) CZ301498B6 (de)
DE (1) DE60006649T2 (de)
DK (1) DK1157023T3 (de)
EE (1) EE04852B1 (de)
ES (1) ES2209831T3 (de)
GE (1) GEP20033067B (de)
HK (1) HK1038923B (de)
HU (1) HUP0200076A3 (de)
ID (1) ID29829A (de)
IL (1) IL144501A0 (de)
LT (1) LT4944B (de)
LV (1) LV12755B (de)
MX (1) MXPA01008374A (de)
MY (1) MY120601A (de)
NO (1) NO320806B1 (de)
NZ (1) NZ513629A (de)
PE (1) PE20001546A1 (de)
PL (1) PL212545B1 (de)
PT (1) PT1157023E (de)
RU (1) RU2253652C2 (de)
SK (1) SK287200B6 (de)
TR (1) TR200102401T2 (de)
TW (1) TWI270546B (de)
UY (1) UY26024A1 (de)
WO (1) WO2000050423A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753546B2 (en) * 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
CN1190440C (zh) 2000-09-22 2005-02-23 生物技术研究有限公司(Gbf) 三唑并一依泊昔酮
AU2002213248A1 (en) * 2000-10-13 2002-04-22 The University Of Mississipi Synthesis of epothilones and relates analogs
KR20030071853A (ko) * 2001-01-25 2003-09-06 브리스톨-마이어스스퀴브컴파니 에포틸론 유사체를 함유한 비경구용 제제
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
KR20040028720A (ko) * 2001-02-20 2004-04-03 브리스톨-마이어스스퀴브컴파니 치료불응성 종양 치료용 에포틸론 유도체
HUP0303175A2 (hu) 2001-02-20 2003-12-29 Bristol-Myers Squibb Co. Epotilonszármazékok alkalmazása makacs tumorok kezelésére alkalmas gyógyszerkészítmény előállítására
CA2440555A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
KR20040078123A (ko) * 2002-01-14 2004-09-08 노파르티스 아게 에포틸론 및 대사길항물질을 포함하는 조합물
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003212457A1 (en) * 2002-03-01 2003-09-16 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
CN1939299A (zh) * 2002-03-08 2007-04-04 诺瓦提斯公司 包含埃坡霉素衍生物和烷化剂的组合
EP1854464A3 (de) * 2002-03-08 2008-06-04 Novartis AG Zubereitungen mit Epothilonderivaten
US6719540B2 (en) 2002-03-12 2004-04-13 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
BR0309711A (pt) * 2002-05-01 2005-02-09 Novartis Ag Método para o tratamento de doenças do câncer
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
SI1767535T1 (sl) 2002-08-23 2010-03-31 Sloan Kettering Inst Cancer Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RU2368661C2 (ru) 2002-09-23 2009-09-27 Бристол-Маерс Сквибб Компани Способы получения, выделения и очистки эпотилона b и рентгеноструктурные кристаллические структуры эпотилона в
MXPA05003706A (es) * 2002-10-09 2005-07-01 Kosan Biosciences Inc Epo d+5-fu/gemcitabina.
DE602004028907D1 (de) 2003-02-06 2010-10-14 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (de) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Epothilonen zur Behandlung von neuronalen Konnektivitätsdefekten wie zum Beispiel Schizophrenie und Autismus
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
HRP20080349T3 (hr) * 2004-11-18 2009-01-31 Bristol-Myers Squibb Company Zrna premazana enteričkom smjesom koja sadrže iksabepilon
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
EP1883627B1 (de) 2005-05-18 2018-04-18 Pharmascience Inc. An die bir-domäne bindende verbindungen
AU2006318284A1 (en) * 2005-11-22 2007-05-31 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
SG171682A1 (en) 2006-05-16 2011-06-29 Aegera Therapeutics Inc Iap bir domain binding compounds
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
US8143415B2 (en) * 2007-05-25 2012-03-27 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
JP2011509299A (ja) 2008-01-08 2011-03-24 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
PL2276485T3 (pl) * 2008-04-24 2014-12-31 Bristol Myers Squibb Co Stosowanie epotilonu D w leczeniu chorób związanych z Tau, w tym choroby Alzheimera
CN102105787A (zh) * 2008-05-29 2011-06-22 百时美施贵宝公司 用于预测患者对共刺激通道调节的应答的方法
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
CN102822200A (zh) 2009-07-20 2012-12-12 百时美施贵宝公司 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EP3444242A3 (de) 2009-11-05 2019-03-20 Rhizen Pharmaceuticals S.A. Neue benzopyran kinase inhibitoren
EP3263583A1 (de) 2010-02-12 2018-01-03 Pharmascience Inc. Iap-bir-domänen bindende verbindungen
WO2011146382A1 (en) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
EP2571878B1 (de) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Neuartige 3,5-disubstituierte-3h-imidazo[4,5-b]pyridin- und 3,5- disubstituierte -3h-[1,2,3]triazol[4,5-b]pyridin- verbindungen als proteinkinasemodulatoren
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
PT2705029T (pt) 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
KR20140144726A (ko) 2012-03-30 2014-12-19 리젠 파마슈티컬스 소시에떼 아노님 C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
CN104768962B (zh) 2012-11-17 2017-04-05 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
US20170355768A1 (en) 2014-12-04 2017-12-14 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
WO2017003990A1 (en) 2015-06-29 2017-01-05 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
CN105153177B (zh) * 2015-09-28 2017-08-08 湖南大学 呋喃并色满肟烯/炔丙基醚及其制备方法与应用
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE75883C (de) W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen Ofen zur Erzeugung von Cyanammonium
DE301115C (de)
GB8909737D0 (en) * 1989-04-27 1989-06-14 Shell Int Research Thiazole derivatives
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
ES2178093T5 (es) 1995-11-17 2009-02-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Derivados de epotilon y su preparacion.
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19707303B4 (de) 1997-02-11 2006-05-11 Mitteldeutsches Bitumenwerk Gmbh Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
CA2281105A1 (en) 1997-02-25 1998-09-03 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilones with a modified side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
PT1001951E (pt) 1997-07-16 2003-02-28 Schering Ag Derivados de tiazolo, processo para a sua preparacao e utilizacao
IL134419A0 (en) 1997-08-09 2001-04-30 Schering Ag Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
HUP0200296A2 (en) * 1998-12-23 2002-05-29 Bristol Myers Squibb Co Microbial transformation method for the preparation of an epothilone

Also Published As

Publication number Publication date
PL350179A1 (en) 2002-11-18
NO320806B1 (no) 2006-01-30
LT4944B (lt) 2002-08-26
CA2360452A1 (en) 2000-08-31
AR028815A1 (es) 2003-05-28
DE60006649T2 (de) 2004-09-30
MY120601A (en) 2005-11-30
PL212545B1 (pl) 2012-10-31
JP2002537395A (ja) 2002-11-05
TR200102401T2 (tr) 2001-12-21
KR20010102199A (ko) 2001-11-15
JP4598957B2 (ja) 2010-12-15
WO2000050423A1 (en) 2000-08-31
ID29829A (id) 2001-10-11
CO5140093A1 (es) 2002-03-22
IL144501A0 (en) 2002-05-23
BG64987B1 (bg) 2006-11-30
HK1038923B (en) 2004-03-19
KR100685336B1 (ko) 2007-02-23
GEP20033067B (en) 2003-09-25
CA2360452C (en) 2011-07-26
LV12755B (lv) 2002-04-20
HUP0200076A2 (hu) 2002-12-28
BR0008379A (pt) 2002-09-24
LV12755A (en) 2001-11-20
EE200100437A (et) 2002-12-16
EE04852B1 (et) 2007-06-15
CN1341114A (zh) 2002-03-20
US6262094B1 (en) 2001-07-17
NO20014017D0 (no) 2001-08-17
TWI270546B (en) 2007-01-11
HUP0200076A3 (en) 2003-01-28
AU3234800A (en) 2000-09-14
PT1157023E (pt) 2004-03-31
NZ513629A (en) 2004-01-30
CZ20012991A3 (cs) 2002-01-16
EP1157023A1 (de) 2001-11-28
PE20001546A1 (es) 2001-03-18
DK1157023T3 (da) 2004-03-29
CN1205208C (zh) 2005-06-08
AU771089B2 (en) 2004-03-11
NO20014017L (no) 2001-10-17
SK10782001A3 (sk) 2002-03-05
SK287200B6 (sk) 2010-03-08
LT2001086A (en) 2002-04-25
HK1038923A1 (en) 2002-04-04
UY26024A1 (es) 2000-09-29
EP1157023B1 (de) 2003-11-19
BG105830A (en) 2002-03-29
CZ301498B6 (cs) 2010-03-24
MXPA01008374A (es) 2003-06-06
DE60006649D1 (de) 2003-12-24
RU2253652C2 (ru) 2005-06-10
ES2209831T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
ATE254615T1 (de) C-21 modifizierte epothilone
EP1392664A4 (de) Epothilonderivate
ATE426598T1 (de) Epothilonderivate
DK1244641T3 (da) Thiazolylamid-derivater
DK1589017T3 (da) 12,13-modificerede epothilon-derivater
AU8181701A (en) Benzothiazole derivatives
AU2001266583A1 (en) Epothilone derivatives and methods for making and using the same
NO20000885L (no) 4-Fenyl-pyridin-derivater
NO20021077L (no) Amino-triazolopyridin-derivater
NO20014408L (no) Hydraulisk forlengelsessensor
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
ATE257148T1 (de) Propargyletherderivate
NO20004875D0 (no) Hydraulisk kalibrering av ekvivalent tetthet
DK1246817T3 (da) 4-Phenyl-1-piperazinyl, -piperidinyl og - tetrahydropyridyl derivater
ATE254598T1 (de) 4-hydroxybiphenylhydrazid-derivate
ATE293592T1 (de) Resorcinderivate
AU2003294938A8 (en) Epothilone derivatives
DE60004451D1 (de) Isothiazolonkonzentrate
DK1189886T3 (da) Ethansulfonyl-piperidinderivater
NO20022867D0 (no) Syklopentenon-derivater
DK1196403T3 (da) Antipsykotiske N-aralkylaminer
ATE361735T1 (de) Wiederverschliessbarer absorbierender artikel
NO20022682D0 (no) Heterosykliske derivater
ATE217621T1 (de) Thiazol-derivate
SK2295U (sk) Trojvrstvový materiál

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1157023

Country of ref document: EP

EEFA Change of the company name